Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies.
Adult
Aged
Bronchodilator Agents
Drug Administration Schedule
Drug Combinations
Female
Glycopyrrolate
/ therapeutic use
Humans
Indans
/ therapeutic use
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Quinolones
/ therapeutic use
Randomized Controlled Trials as Topic
Respiratory Function Tests
Respiratory System Agents
/ therapeutic use
Severity of Illness Index
Treatment Outcome
Bronchodilator
COPD
indacaterol/glycopyrrolate
reversibility
Journal
COPD
ISSN: 1541-2563
Titre abrégé: COPD
Pays: England
ID NLM: 101211769
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
28
6
2019
medline:
21
4
2020
entrez:
28
6
2019
Statut:
ppublish
Résumé
Bronchodilator reversibility occurs in patients with COPD. Pooled analysis of two 12-week, placebo-controlled randomised studies (FLIGHT1 [NCT01727141]; FLIGHT2 [NCT01712516]) assessed the effect of bronchodilator reversibility on lung function, patient-reported outcomes, and safety in 2,043 patients with moderate-to-severe COPD treated with indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 µg twice daily. Reversibility was defined as post-bronchodilator increase in forced expiratory volume in one second (FEV
Identifiants
pubmed: 31242792
doi: 10.1080/15412555.2019.1612341
doi:
Substances chimiques
Bronchodilator Agents
0
Drug Combinations
0
Indans
0
Quinolones
0
Respiratory System Agents
0
indacaterol
8OR09251MQ
Glycopyrrolate
V92SO9WP2I
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM